Osteoblasts stimulate the osteogenic and metastatic progression of castration-resistant prostate cancer in a novel model for in vitro and in vivo studies

Clinical and Experimental Metastasis

Volumn 31, Issue 3, 2014, Pages 269-283

  Hagberg Thulin, Malin ^a   Jennbacken, Karin ^a   Damber, Jan Erik ^a   Welén, Karin ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Bone metastasis; Castration resistant prostate cancer; Osteoblasts; Osteomimicry

Indexed keywords

OSTEOCALCIN; PROSTATE SPECIFIC ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE DEVELOPMENT; BONE METASTASIS; CANCER CELL CULTURE; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; CELL STIMULATION; CELL STRAIN LNCAP; CELL STRAIN LNCAP 19; CONTROLLED STUDY; CULTURE MEDIUM; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR MIMICRY; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOMIMICRY; PHENOTYPE; PROTEIN BLOOD LEVEL; STAINING; TIBIA; TUMOR XENOGRAFT; ANIMAL; BLOOD; BONE TUMOR; CYTOLOGY; DISEASE MODEL; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; METASTASIS; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; BONE NEOPLASMS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; NEOPLASM METASTASIS; OSTEOBLASTS; OSTEOGENESIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84897572526     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-013-9626-1     Document Type: Article

References (47)

1. Michaelson MD, Marujo RM, Smith MR (2004) Contribution of androgen deprivation therapy to elevated osteoclast activity in men with metastatic prostate cancer. Clin Cancer Res 10(8):2705-2708 (Pubitemid 38509145)
2. Vessella RL, Corey E (2006) Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis. Clin Cancer Res 12(20 Pt 2):6285s-6290s. doi:10. 1158/1078-0432.CCR-06-0813
3. Oefelein MG, Ricchuiti V, Conrad W, Seftel A, Bodner D, Goldman H, Resnick M (2001) Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol 166(5):1724-1728
4. Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2(8):584-593. doi:10.1038/nrc867
5. Roodman GD (2004) Mechanisms of bone metastasis. N Engl J Med 350(16):1655-1664. doi:10.1056/NEJMra030831
6. Jung K, Lein M, Stephan C, Von Hosslin K, Semjonow A, Sinha P, Loening SA, Schnorr D (2004) Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer 111(5):783-791. doi:10.1002/ijc.20314 (Pubitemid 39062904)
7. Roudier MP, True LD, Higano CS, Vesselle H, Ellis W, Lange P, Vessella RL (2003) Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol 34(7):646-653 (Pubitemid 36875509)
8. Shimazaki J, Higa T, Akimoto S, Masai M, Isaka S (1992) Clinical course of bone metastasis from prostatic cancer following endocrine therapy: examination with bone X-ray. Adv Exp Med Biol 324:269-275 (Pubitemid 23007168)
9. Autzen P, Robson CN, Bjartell A, Malcolm AJ, Johnson MI, Neal DE, Hamdy FC (1998) Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies. Br J Cancer 78(9):1219-1223 (Pubitemid 28479155)
10. Lee HL, Pienta KJ, Kim WJ, Cooper CR (2003) The effect of bone-associated growth factors and cytokines on the growth of prostate cancer cells derived from soft tissue versus bone metastases in vitro. Int J Oncol 22(4):921-926
11. Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, Simons JW (1995) Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1(9):944-949
12. Fizazi K, Yang J, Peleg S, Sikes CR, Kreimann EL, Daliani D, Olive M, Raymond KA, Janus TJ, Logothetis CJ, Karsenty G, Navone NM (2003) Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clin Cancer Res 9(7):2587-2597 (Pubitemid 36842101)
13. Wang G, Haile S, Comuzzi B, Tien AH, Wang J, Yong TM, Jelescu-Bodos AE, Blaszczyk N, Vessella RL, Masri BA, Sadar MD (2009) Osteoblast-derived factors induce an expression signature that identifies prostate cancer metastasis and hormonal progression. Cancer Res 69(8):3433-3442. doi:10.1158/0008-5472.CAN-08- 3506
14. Clines GA, Guise TA (2005) Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. Endocr Relat Cancer 12(3):549-583. doi:10.1677/erc.1.00543 (Pubitemid 41482993)
15. Gardner TA, Lee SJ, Lee SD, Li X, Shirakawa T, Kwon DD, Park RY, Ahn KY, Jung C (2009) Differential expression of osteocalcin during the metastatic progression of prostate cancer. Oncol Rep 21(4):903-908
16. Koeneman KS, Yeung F, Chung LWK (1999) Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 39(4):246-261 (Pubitemid 29244499)
17. Rucci N, Teti A (2010) Osteomimicry: how tumor cells try to deceive the bone. Front Biosci (Schol Ed) 2:907-915
18. Corey E, Quinn JE, Bladou F, Brown LG, Roudier MP, Brown JM, Buhler KR, Vessella RL (2002) Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells. Prostate 52(1):20-33. doi:10.1002/pros.10091 (Pubitemid 34553189)
19. Yang J, Fizazi K, Peleg S, Sikes CR, Raymond AK, Jamal N, Hu M, Olive M, Martinez LA, Wood CG, Logothetis CJ, Karsenty G, Navone NM (2001) Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway. Cancer Res 61(14):5652-5659 (Pubitemid 32694953)
20. Al Nakouzi N, Bawa O, Le Pape A, Lerondel S, Gaudin C, Opolon P, Gonin P, Fizazi K, Chauchereau A (2012) The IGR-CaP1 xenograft model recapitulates mixed osteolytic/blastic bone lesions observed in metastatic prostate cancer. Neoplasia 14(5):376-387
21. Raheem O, Kulidjian AA, Wu C, Jeong YB, Yamaguchi T, Smith KM, Goff D, Leu H, Morris SR, Cacalano NA, Masuda K, Jamieson CH, Kane CJ, Jamieson CA (2011) A novel patient-derived intrafemoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions. J Transl Med 9:185. doi:10.1186/1479-5876-9-185
22. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, Pathak S, von Eschenbach AC, Chung LW (1994) Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 54(10):2577-2581 (Pubitemid 24173741)
23. Gustavsson H, Welen K, Damber JE (2005) Transition of an androgen-dependent human prostate cancer cell line into an androgen-independent subline is associated with increased angiogenesis. Prostate 62(4):364-373. doi:10.1002/pros.20145 (Pubitemid 40227488)
24. Jennbacken K, Gustavsson H, Welen K, Vallbo C, Damber JE (2006) Prostate cancer progression into androgen independency is associated with alterations in cell adhesion and invasivity. Prostate 66(15):1631-1640. doi:10.1002/Pros.20469 (Pubitemid 44646354)
25. Gustavsson H, Jennbacken K, Welen K, Damber JE (2008) Altered expression of genes regulating angiogenesis in experimental androgen-independent prostate cancer. Prostate 68(2):161-170. doi:10.1002/Pros.20672 (Pubitemid 351186228)
26. Jennbacken K, Tesan T, Wang WZ, Gustavsson H, Damber JE, Welen K (2010) N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer. Endocr Relat Cancer 17(2):469-479. doi:10.1677/Erc-10-0015
27. Jennbacken K, Welen K, Olsson A, Axelsson B, Torngren M, Damber JE, Leanderson T (2011) Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod (ABR-215050). Prostate. doi:10.1002/pros.21495
28. Lin DL, Tarnowski CP, Zhang J, Dai JL, Rohn E, Patel AH, Morris MD, Keller ET (2001) Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. Prostate 47(3):212-221. doi:10.1002/pros.1065 (Pubitemid 32378373)
29. Thalmann GN, Sikes RA, Devoll RE, Kiefer JA, Markwalder R, Klima I, Farach-Carson CM, Studer UE, Chung LWK (1999) Osteopontin: possible role in prostate cancer progression. Clin Cancer Res 5(8):2271-2277 (Pubitemid 29399287)
30. Thomas R, True LD, Bassuk JA, Lange PH, Vessella RL (2000) Differential expression of osteonectin/SPARC during human prostate cancer progression. Clin Cancer Res 6(3):1140-1149 (Pubitemid 30159378)
31. Barnes GL, Hebert KE, Kamal M, Javed A, Einhorn TA, Lian JB, Stein GS, Gerstenfeld LC (2004) Fidelity of Runx2 activity in breast cancer cells is required for the generation of metastases-associated osteolytic disease. Cancer Res 64(13):4506-4513. doi:10.1158/0008-5472.CAN-03-3851 (Pubitemid 38856922)
32. Javed A, Barnes GL, Pratap J, Antkowiak T, Gerstenfeld LC, van Wijnen AJ, Stein JL, Lian JB, Stein GS (2005) Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo. Proc Natl Acad Sci USA 102(5):1454-1459. doi:10.1073/pnas.0409121102 (Pubitemid 40209191)
33. Pratap J, Imbalzano KM, Underwood JM, Cohet N, Gokul K, Akech J, van Wijnen AJ, Stein JL, Imbalzano AN, Nickerson JA, Lian JB, Stein GS (2009) Ectopic runx2 expression in mammary epithelial cells disrupts formation of normal acini structure: implications for breast cancer progression. Cancer Res 69(17):6807-6814. doi:10.1158/0008-5472.CAN-09-1471
34. Akech J, Wixted JJ, Bedard K, van der Deen M, Hussain S, Guise TA, van Wijnen AJ, Stein JL, Languino LR, Altieri DC, Pratap J, Keller E, Stein GS, Lian JB (2010) Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene 29(6):811-821. doi:10.1038/onc.2009.389
35. Baniwal SK, Khalid O, Gabet Y, Shah RR, Purcell DJ, Mav D, Kohn-Gabet AE, Shi Y, Coetzee GA, Frenkel B (2010) Runx2 transcriptome of prostate cancer cells: insights into invasiveness and bone metastasis. Mol Cancer 9:258. doi:10.1186/1476-4598-9-258
36. Dunstan CR, Boyce R, Boyce BF, Garrett IR, Izbicka E, Burgess WH, Mundy GR (1999) Systemic administration of acidic fibroblast growth factor (FGF-1) prevents bone loss and increases new bone formation in ovariectomized rats. J Bone Miner Res 14(6):953-959. doi:10.1359/jbmr.1999.14.6.953 (Pubitemid 29262890)
37. Guise TA, Mohammad KS, Clines G, Stebbins EG, Wong DH, Higgins LS, Vessella R, Corey E, Padalecki S, Suva L, Chirgwin JM (2006) Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 12(20):6213s-6216s. doi:10.1158/1078-0432.Ccr-06-1007 (Pubitemid 44703792)
38. Lee YC, Cheng CJ, Huang M, Bilen MA, Ye XC, Navone NM, Chu K, Kao HH, Yu-Lee LY, Wang ZX, Lin SH (2010) Androgen depletion up-regulates cadherin-11 expression in prostate cancer. J Pathol 221(1):68-76. doi:10.1002/Path.2687
39. Huang CF, Lira C, Chu K, Bilen MA, Lee YC, Ye XC, Kim SM, Ortiz A, Wu FLL, Logothetis CJ, Yu-Lee LY, Lin SH (2010) Cadherin-11 increases migration and invasion of prostate cancer cells and enhances their interaction with osteoblasts. Cancer Res 70(11):4580-4589. doi:10.1158/0008-5472.Can-09-3016
40. Thiolloy S, Edwards JR, Fingleton B, Rifkin DB, Matrisian LM, Lynch CC (2012) An osteoblast-derived proteinase controls tumor cell survival via TGF-beta activation in the bone microenvironment. PLoS ONE 7(1):e29862. doi:10.1371/journal.pone.0029862
41. Wang D, Christensen K, Chawla K, Xiao G, Krebsbach PH, Franceschi RT (1999) Isolation and characterization of MC3T3-E1 preosteoblast subclones with distinct in vitro and in vivo differentiation/mineralization potential. J Bone Miner Res 14(6):893-903. doi:10.1359/jbmr.1999.14.6.893 (Pubitemid 29262883)
42. Roudier MP, Morrissey C, True LD, Higano CS, Vessella RL, Ott SM (2008) Histopathological assessment of prostate cancer bone osteoblastic metastases. J Urol 180(3):1154-1160. doi:10.1016/j.juro.2008.04.140
43. Magnusson P, Larsson L, Englund G, Larsson B, Strang P, Selin-Sjogren L (1998) Differences of bone alkaline phosphatase isoforms in metastatic bone disease and discrepant effects of clodronate on different skeletal sites indicated by the location of pain. Clin Chem 44(8 Pt 1):1621-1628 (Pubitemid 28381203)
44. Stein GS, Lian JB, Stein JL, Van Wijnen AJ, Montecino M (1996) Transcriptional control of osteoblast growth and differentiation. Physiol Rev 76(2):593-629 (Pubitemid 26163716)
45. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93(2):165-176 (Pubitemid 28180851)
46. Honore P, Luger NM, Sabino MAC, Schwei MJ, Rogers SD, Mach DB, O'Keefe PF, Ramnaraine ML, Clohisy DR, Mantyh PW (2000) Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med 6(5):521-528 (Pubitemid 30305901)
47. Pfitzenmaier J, Quinn JE, Odman AM, Zhang J, Keller ET, Vessella RL, Corey E (2003) Characterization of C4-2 prostate cancer bone metastases and their response to castration. J Bone Miner Res 18(10):1882-1888. doi:10.1359/jbmr.2003.18.10.1882 (Pubitemid 37322566)